Granules India Limited announced that Gagillapur facility located at Hyderabad, Telangana, India has completed the U.S. Food and Drug Administration's Pre-Approval Inspection (PAI) from January 9, 2023 to January 13, 2023 with 3 observations and the Company will respond to these observations within the stipulated time period. Gagillapur facility manufactures Finished Dosages (FDs) and Pharmaceutical Formulation Intermediates (PFIs).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
495.2 INR | +0.18% | +1.60% | +22.16% |
15/05 | Transcript : Granules India Limited, Q4 2024 Earnings Call, May 15, 2024 | |
15/05 | Granules India Posts Decline in Fiscal Q4 Consolidated Net Profit, Revenue | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.16% | 1.43B | |
+56.86% | 815B | |
+43.90% | 641B | |
-6.57% | 352B | |
+17.32% | 314B | |
+9.94% | 303B | |
+16.08% | 242B | |
+2.29% | 224B | |
+13.96% | 218B | |
+7.98% | 168B |
- Stock Market
- Equities
- GRANULES Stock
- News Granules India Limited
- Granules India Limited Announces That Gagillapur Facility Located At Hyderabad, Telangana, India Completes the U.S. Food and Drug Administration's Pre-Approval Inspection from January 9, 2023 to January 13, 2023